IN8bio to present GBM clinical data and TCE platform at ASCO and R&D Day
IN8bio (Nasdaq: INAB) has announced a slate of conference presentations and an in-house R&D Day running from May to June 2026, at which the New York-based clinical-stage company will disclose new clinical data from its gamma-delta (γδ) T cell programme in glioblastoma and provide an update on its nascent T cell engager (TCE) platform.
The centrepiece of the conference run is a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on 1 June, covering Phase I data on INB-200 — an autologous gene-modified γδ T cell candidate for newly diagnosed glioblastoma multiforme (GBM). The abstract, to be presented by Louis B. Nabors MD, will characterise the cell product and early clinical findings from the study. INB-200 is part of the company's INB-200/400 programme and has previously generated what IN8bio describes as observed survival benefits in DeltEx DRI-treated GBM patients — a claim the company has not yet supported with peer-reviewed trial data.
R&D Day and earlier conference appearances
Ahead of ASCO, IN8bio will host its own R&D Day on 21 May in New York, running from 9:00 AM to 11:30 AM EDT and available both in-person and virtually. The session will cover the company's TCE platform, anchored by INB-600, which management says is designed to recruit γδ T cells rather than the conventional αβ T cells targeted by most approved bispecific engagers. A clinical perspective on the GBM programme will be provided by Dr David Reardon, Director of the Centre for Neuro-Oncology at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School — a notable external validator for an early-stage company.
Two further poster presentations at the International Society for Cell & Gene Therapy (ISCT) Annual Meeting in Dublin on 7 May will cover γδ T cell therapy outcomes in glioblastoma and digital infrastructure for early-stage cell and gene therapy (CGT) companies. An oral presentation at the American Society of Gene & Cell Therapy (ASGCT) meeting in Boston on 14 May will address the potential role of γδ T cells in shifting treatment dynamics in GBM.
Market context and competitive landscape
GBM remains one of oncology's most intractable indications. Standard-of-care temozolomide-based chemoradiotherapy has not materially improved in decades, and the indication has claimed several high-profile clinical failures, including checkpoint inhibitor programmes. The bar for clinical differentiation is correspondingly high, and investors will scrutinise the ASCO Phase I data for evidence of durable response and a manageable safety profile before drawing conclusions about INB-200's commercial potential.
The TCE space more broadly is crowded. Several pharmaceutical majors and well-capitalised biotechs are advancing αβ T cell-recruiting bispecifics across haematological and solid tumour indications, with a handful already approved by the FDA and EMA. IN8bio's thesis — that γδ T cells can overcome some of the cytokine-release and on-target off-tumour liabilities associated with conventional TCEs — is scientifically plausible but clinically unproven at scale. The INB-600 platform is preclinical, and the company will need to demonstrate translational credibility at the R&D Day to build the case with institutional investors.
Chief executive William Ho said the presentations "highlight the progress we are making with our novel TCE program, complemented by translational advances in our clinical program supporting the observed survival benefits in DeltEx DRI treated glioblastoma patients."
With a pipeline spanning GBM, high-risk leukaemia (INB-100, an allogeneic γδ candidate for haploidentical stem cell transplant settings), and the nascent TCE platform, IN8bio carries a broad early-stage portfolio for a company of its size. The coming weeks of conference data will be a material test of investor appetite ahead of any future financing round.